MenÉndez, Pablo
Research Professor
Life & Medical Sciences
Institucio Catalana de Recerca i Estudis Avancats
Spain
Biography
Born in Avilés, Asturias, in 1974. Biochemist by University of Salamanca (1997) and PhD in Medicine (Hematology) by the same University in 2002, under the supervision of Prof. Alberto Orfao and Prof. Jesus San Miguel. Postdoctoral training in stem cell biology (Mick Bhatia Laboratory, London, ON, Canada; 2002-2005) and in childhood leukemia (Mel Greaves Laboratory, London, UK; 2005-2007). In 2007, I was appointed Director of the Andalusian Stem Cell Bank, and was leading my own lab at CIBM (Granada, Spain) until July 2011 when I moved to GENyO (Granada, Spain) as Principal Invesigator. In June 2013 I was appointed ICREA Research Professor and Research Director of The Josep Carreras Leukemia Research Institute-Campus Clínic, Barcelona, Spain.
Research Interest
1.-Modeling Infant Acute Lymphoblastic Leukemia MLL-AF4+. 2.-Sarcomagenesis models based on mesenchymal stem cells. 3.-Leukemic cell-niche environment interactions. 4.-Deciphering the intrinsic determinants and signaling pathways underlying hematopoietic-mesenchymal specification from human PSCs 5.- Adoptive T-cell-based CAR immunotherapy for B-cell ALL and AML.
Publications
-
A. Muñoz-Lopez, D. Romero, C. Prieto, V. Ramos-MejÃa, A. Agraz-Doblas, I. Varela, M. Buschbeck, A. Palau, X. Carvajal-Vergara, A. Giorgetti, A. Ford, M. Lako, I. Granada, S. RodrÃguez-Perales, R Stam, M. Fraga, M. Nakanishi, G. Cazzaniga, M. Bardini, I. Cobo, G Bayon, A. Fernandez, C. Bueno, P. Menendez*. Differentiation refractoriness of MLL-rearranged human B-cell acute leukemias to reprogramming into pluripotency. Stem Cell Rep 2016;7:602-18. I.F. 7.05
-
A Matas, A Vidal, V Rodriguez, N Villamor, J Delgado, E Gine, Heleia Roca, P Menéndez, E Campo, A López-Guillermo, D Colomer, G Roué, A Wiestner, P Parren, P Doshi, J Lammerts, P Pérez-Galán. The human CD38 monoclonal antibody daratumumab 1 shows anti-tumor activity and hampers leukemia microenvironment interactions in chronic lymphocytic leukemia. Clin Cancer Res; 2016
-
A. Giorgetti, J Castaño, R Diaz-de la guardia, C Bueno, M Delgado, L Espinosa, P Menendez*. Proinflammatory signaling is dispensable for hematopoietic emergence of human pluripotent stem cells. Exp Hemato; 2017;45:85-93. I.F. 3
